<DOC>
	<DOCNO>NCT01168219</DOCNO>
	<brief_summary>This phase II clinical trial study well give busulfan , fludarabine phosphate , anti-thymocyte globulin follow donor stem cell transplant azacitidine work treat patient high-risk myelodysplastic syndrome older patient acute myeloid leukemia . Giving low dos chemotherapy , busulfan fludarabine phosphate , donor stem cell transplant help stop growth cancer cell . It also stop patient 's immune system reject donor 's stem cell . The donated stem cell may replace patient 's immune cell help destroy remain cancer cell ( graft-vs-tumor effect ) . Sometimes transplanted cell donor also make immune response body 's normal cell . Giving anti-thymocyte globulin transplant give azacitidine , tacrolimus , methotrexate transplant may stop happening .</brief_summary>
	<brief_title>Busulfan , Fludarabine Phosphate , Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant Azacitidine Treating Patients With High-Risk Myelodysplastic Syndrome Older Patients With Acute Myeloid Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVE : I . To determine treatment improve 2-year progression-free survival ( PFS ) patient high risk myelodysplastic syndrome ( MDS ) patient acute myeloid leukemia ( AML ) &gt; = 60 yrs age SECONDARY OBJECTIVES : I . To determine safety feasibility use post-transplantation azacitidine . II . To determine ability use pharmacokinetic-directed busulfan achieve area curve ( AUC ) within 20 % target AUC &gt; 80 % patient . III . To determine rate grade II-IV III-IV acute graft-vs-host disease ( GVHD ) . IV . To determine incidence extensive chronic GVHD . V. To determine treatment-related mortality 100 day 1 year . VI . To determine 5-year overall survival . OUTLINE : REDUCED-INTENSITY CONDITIONING : Patients receive fludarabine phosphate intravenously ( IV ) 30 minute day -7 -3 , busulfan IV 45 minute day -6 -3 , anti-thymocyte globulin IV 4-10 hour day -6 -5 ( match sibling donor [ MSD ] ) -6 -4 ( match unrelated donor [ MUD ] ) . TRANSPLANTATION : Patients undergo allogeneic hematopoietic stem cell transplantation day 0 day 0-1 . GRAFT-VS-HOST DISEASE PROPHYLAXIS : Patients receive tacrolimus orally ( PO ) IV day -2 90 taper day 150-180 . Patients also receive methotrexate IV day 1 , 3 , 6 ( MSD ) , 11 ( MUD ) . CONSOLIDATION : Beginning day 42 , patient receive azacitidine subcutaneously ( SC ) IV day 1-5 . Treatment repeat every 4 week 6 course . Blood bone marrow sample may collect periodically correlative pharmacokinetic study . After completion study treatment , patient follow every 6 month 5 year .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Monocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Erythroblastic , Acute</mesh_term>
	<mesh_term>Leukemia , Megakaryoblastic , Acute</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>Meets one follow set criterion : Myelodysplastic syndrome ( MDS ) : Disease highrisk feature ( found either diagnosis initiation cytotoxic therapy ) , define one following : International prognostic scoring system ( IPSS ) risk &gt; = intermediate2 Refractory anemia excess blast FrenchAmericanBritish ( FAB ) classification Highrisk cytogenetics ( either complex 7 ) Less 10 % bone marrow blast determine bone marrow biopsy within past 4 week ( reduction marrow blast percentage may achieve chemotherapy therapy ) Less 75 year old Acute myeloid leukemia ( AML ) : No FAB M3 No acute leukemia follow blast transformation prior chronic myelogenous leukemia myeloproliferative disease Patients precede MDS treatmentrelated AML eligible Prior central nervous system ( CNS ) involvement allow provided disease remission transplantation Morphologic complete remission ( leukemiafree state ) define meet follow criterion : Bone marrow blast &lt; 5 % ( determine bone marrow within past 4 week ) , without requirement normal peripheral blood count No extramedullary leukemia No blast peripheral blood Achieved complete remission ( CR ) 2 course induction chemotherapy Patients treat azacitidine decitabine achieve leukemiafree state eligible ( may require 4 course therapy reach status ) Age 60 74 year Donors must meet following criterion : One following : HLAidentical sibling ( 6/6 ) serologic type class ( A , B ) lowresolution molecular type class II ( DRB1 ) Matched unrelated donor ( 8/8 ) highresolution molecular typing HLAA , B , C , DRB1 No syngeneic donor Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Calculated creatinine clearance â‰¥ 40 mL/min Bilirubin &lt; 2 mg/dL OR bilirubin 23 mg/dL provide direct bilirubin normal Aspartate aminotransferase ( AST ) &lt; 3 time upper limit normal Diffusing capacity lung carbon monoxide ( DLCO ) &gt; 40 % symptomatic pulmonary disease Left ventricle ejection fraction ( LVEF ) &gt; = 30 % echocardiogram ( ECHO ) multigated acquisition ( MUGA ) Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No uncontrolled diabetes mellitus active serious infection No know hypersensitivity E. coliderived product , azacitidine , mannitol No human immunodeficiency virus ( HIV ) infection active hepatitis B C Prior azacitidine decitabine allow No patient progress MDS AML treatment azacitidine decitabine At least 4 week since prior deoxyribonucleic acid ( DNA ) hypomethylating chemotherapy , radiotherapy , and/or surgery No 2 course consolidation therapy transplantation ( patient AML ) Any consolidation regimen require transplantation use No 6 month documentation morphologic CR transplantation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>